** Shares of genetic testing firm Natera NTRA.O fall 2.3% to $154.80 premarket, as a $96 mln jury verdict against rival CareDx CDNA.O gets overturned

** U.S. District Judge Colm Connolly rules that the patents Natera accused CareDx of infringing were invalid, dismissing Natera's 2024 trial win over patent rights in DNA testing technology for kidney transplants

** Natera plans to appeal the decision and pursue "all available remedies"

** CareDx's attorney said the decision was "the right outcome on the law and for organ transplant patients"

** A jury had previously said that CareDx infringed one of the patents and awarded Natera $96.3 million in damages, but the judge's decision overturned this verdict

** NTRA more than doubled in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))